Zetia and Nexavar drive Bayer's pharma growth in Japan
This article was originally published in Scrip
Bayer's sales of prescription drugs in Japan grew by just over 9% to ¥171.5 billion ($1.83 billion) at reimbursement prices in calendar 2009, with the increase being driven mainly by high cholesterol product Zetia (ezetimibe) and Nexavar (sorafenib) for cancer.
You may also be interested in...
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.